newsfilter
← Latest News
ClinicalTrials.gov·

Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG) - NCT05644561

Plasma Concentration of Ravulizumab, Serum Free C5 Concentration of Ravulizumab, Change From Baseline in The Quantitative Myasthenia Gravis (QMG) Total Score at Up to Week 18, (and 11 more...)